Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-27T14:30:00.805Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost Analysis of Methylprednisolone Treatment of Multiple Sclerosis Patients

Published online by Cambridge University Press:  18 September 2015

Lynda S. Robson ,
Charlene Bain ,
Shann Beck ,
Suzanne Guthrie ,
Peter C. Coyte  and
Paul O'Connor
Lynda S. Robson
Affiliation:
Institute for Work and Health, Toronto
Charlene Bain
Affiliation:
Department of Health Administration
Shann Beck
Affiliation:
Sunnybrook Health Sciences Centre, Toronto
Suzanne Guthrie
Affiliation:
Simcoe County District Health Unit, Orillia
Peter C. Coyte
Affiliation:
Department of Health Administration Institute for Clinical Evaluative Sciences in Ontario, Toronto Hospital Management Research Unit, Institute for Policy Analysis, Centre for the Study of State and Market, University of Toronto Wellesley Hospital Research Unit, Toronto
Paul O'Connor*
Affiliation:
St. Michael's Hospital, Toronto
*
Division of Neurology, St. Michael's Hospital, 30Bond Street, Toronto, Ontario, Canada M5B 1W8
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Intravenous methylprednisolone (IVMP) is the treatment of choice for multiple sclerosis (MS) patients undergoing acute exacerbation of disease symptoms and yet its cost has not been accurately determined. Determination of this cost in different settings is also pertinent to consideration of cost-saving alternatives to in-patient treatment.

Methods:

Cost analysis from the point of view of the health care system of IVMP treatment of MS patients receiving treatment in association with a selected Toronto teaching hospital in fiscal year 1994/95 was carried out. Costs of any concurrent treatments were excluded.

Results:

Total cost for 92 patients, based on a 4 dose regime, was estimated to be $78,527. The the cost per patient was $1,1181.84 for in-patients (IP), $714.64 for out-patients of the MS Clinic (OP) and $774.21 for patients whose treatment was initiated in the Clinic, but completed in the home (HC). Sensitivity analyses indicated: 1) IP treatment was in all cases more expensive than that of OP or HC; 2) the cost savings of OP vs. HC was sensitive to assumptions made regarding Clinic overhead, Clinic nursing costs and Home Care Program overhead.

Conclusion:

Alternatives to in-patient care must be considered carefully. In this study, both out-patient and in-home treatment were cost-saving alternatives to in-patient treatment, but large differences in the cost of hospital out-patient vs. in-home care could not be demonstrated.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 3 , August 1998 , pp. 222 - 229
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Asche, CV, Ho, E, Chan, B, Coyte, PC. The economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95: 268–274.CrossRefGoogle ScholarPubMed
2.Matthews, WB, Compston, A, Allen, IV, Martyn, CN. McAlpine’s Multiple Sclerosis. New York: Churchill Livingston, Second Edition, 1991:259.Google Scholar
3.Alam, SM, Kyriakides, T, Lawden, M, Newman, PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219–1220.CrossRefGoogle ScholarPubMed
4.Beck, RW, Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis: a need to change treatment practices. Neurology 1992; 42: 1133–1135.CrossRefGoogle Scholar
5.Beck, R, Geary, P, Trobe, J, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329: 1764–1769.CrossRefGoogle ScholarPubMed
6.Durelli, L, Cocito, D, Riccio, A, et al. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinicalimmunologic correlations. Neurology 1986; 36: 238–243.CrossRefGoogle ScholarPubMed
7.Milligan, NM, Newcombe, R, Compston, DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511–516.CrossRefGoogle ScholarPubMed
8.Ohno, R, Hamaguchi, K, Sowa, K, Tanada, H, Watanabe, Y. Highdose intravenous corticosteroids in the treatment of multiple sclerosis. Jpn J Med 1987; 26: 212–216.CrossRefGoogle ScholarPubMed
9.Goodin, DS. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology 1991; 41; 980–985.CrossRefGoogle ScholarPubMed
10.Health Services Utilization and Research Commission (HSURC). The Cost-Effectiveness of Home Care. A Rigorous Review of the Literature. Saskatchewan: HSURC, 1996.Google Scholar
11.Boyle, MH, Torrance, GW, Horwood, SP, Sinclair, JC. A cost analysis of providing neonatal intensive care (NIC) to 500-1499 gram birth weight infants. QSEP Research Report, No. 51. Hamilton, Ontario, Canada, Program for Quantitative Studies in Economics and Population, 1982.Google Scholar
12.Drummond, MF, Stoddart, GL, Torrance, GW. Methods for the Evaluation of Health Care Programmes. Toronto: Oxford University Press, 1987.Google Scholar
13.Ontario Hospital Association. Ontario Guide to Case Costing. Toronto: Ontario Hospital Association, 1995.Google Scholar
14.Ontario Ministry of Health: Schedule of Benefits: Physician Services Under the Health Insurance Act. October 1, 1992.Google Scholar
15.Fulcher, DA, Katelaris, CH. Anaphylactoid reaction to intravenous hydrocortisone sodium succinate: a case report and literature review. Med J Aust 1991; 154: 210–214.CrossRefGoogle ScholarPubMed
16.White, KP, Driscoll, MS, Rothe, MJ, Grant-Kels, JM. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30: 768–773.CrossRefGoogle ScholarPubMed
17.Ferris, F, Wodinsky, H, Kea, I, et al. A cost-minimization study of cancer patients requiring a narcotic infusion in hospital and at home. J Clin Epidemiol 1991; 44: 313–327.CrossRefGoogle ScholarPubMed
18.Sheldon, P, Bender, M. High-technology in home care: an overview of intravenous therapy. Nursing Clinics N America 1994; 29: 507–519.CrossRefGoogle ScholarPubMed
19.Milkovich, G. Outpatient parenteral antibiotic therapy. Management of serious infection. Part I: Medical, socioeconomic, and legal issues. Costs and benefits. Hospital Practice 1993; 28: 39–43.CrossRefGoogle ScholarPubMed